You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Go to Close Top

SHINGRIX tolerability and safety profile

The safety of SHINGRIX was extensively studied in 2 large phase III clinical trials 1, 2

The tolerability and safety of SHINGRIX was evaluated by pooling data from two pivotal Phase III placebo-controlled clinical studies, ZOE-50 and ZOE-70, involving subjects aged ≥50 who received at least one dose of SHINGRIX (n=14,645) or placebo (n=14,660) administered on a 0- and 2-month schedule. 1, 2

Reference:

  1. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
  2. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375(11):1019-32.